UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study

British journal of dermatology (1951), 2013-02, Vol.168 (2), p.402-411

2013

Volltextzugriff (PDF)

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials

British journal of dermatology (1951), 2015-10, Vol.173 (4), p.949-961

2015

Volltextzugriff (PDF)

Secukinumab is superior to fumaric acid esters in treating patients with moderate‐to‐severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial

British journal of dermatology (1951), 2017-10, Vol.177 (4), p.1024-1032

2017

Volltextzugriff (PDF)

Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study

Journal of the European Academy of Dermatology and Venereology, 2013-03, Vol.27 (3), p.e376-e383

2013

Volltextzugriff (PDF)

Secukinumab sustains good efficacy and favourable safety in moderate‐to‐severe psoriasis after up to 3 years of treatment: results from a double‐blind extension study

British journal of dermatology (1951), 2017-10, Vol.177 (4), p.1033-1042

2017

Volltextzugriff (PDF)

Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest

Archives of Dermatological Research, 2015-12, Vol.307 (10), p.875-883

2015

Volltextzugriff (PDF)

Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials

Journal of the European Academy of Dermatology and Venereology, 2021-02, Vol.35 (2), p.476-485

2021

Volltextzugriff (PDF)

Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis: results from a phase IIa open‐label trial and subsequent phase III open‐label extension

British journal of dermatology (1951), 2020-01, Vol.182 (1), p.85-96

2020

Volltextzugriff (PDF)

Addressing challenges associated with long‐term topical treatment and benefits of proactive management in patients with psoriasis

Journal of the European Academy of Dermatology and Venereology, 2021-02, Vol.35 (S1), p.35-41

2021

Volltextzugriff (PDF)

Gender and age significantly determine patient needs and treatment goals in psoriasis – a lesson for practice

Journal of the European Academy of Dermatology and Venereology, 2019-04, Vol.33 (4), p.700-708

2019

Volltextzugriff (PDF)

Five‐year efficacy and safety of tildrakizumab in patients with moderate‐to‐severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)

British journal of dermatology (1951), 2021-08, Vol.185 (2), p.323-334

2021

Volltextzugriff (PDF)

Combined culture and metagenomic analyses reveal significant shifts in the composition of the cutaneous microbiome in psoriasis

British journal of dermatology (1951), 2019-12, Vol.181 (6), p.1254-1264

2019

Volltextzugriff (PDF)

Direct comparison of risankizumab and fumaric acid esters in systemic therapy–naïve patients with moderate‐to‐severe plaque psoriasis: a randomized controlled trial

British journal of dermatology (1951), 2022-01, Vol.186 (1), p.30-39

2022

Volltextzugriff (PDF)

Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial

Journal of the American Academy of Dermatology, 2023-09, Vol.89 (3), p.486-495

2023

Volltextzugriff (PDF)

Alopecia areata development in atopic dermatitis patients treated with dupilumab

Journal of the European Academy of Dermatology and Venereology, 2020-10, Vol.34 (10), p.e612-e613

2020

Volltextzugriff (PDF)

Psoriasis patients show signs of insulin resistance

British journal of dermatology (1951), 2007-12, Vol.157 (6), p.1249-1251

2007

Volltextzugriff (PDF)

Topology of psoriasis in routine care: results from high‐resolution analysis of 2009 patients

British journal of dermatology (1951), 2019-08, Vol.181 (2), p.358-365

2019

Volltextzugriff (PDF)

Psoriasis: a possible risk factor for development of coronary artery calcification

British journal of dermatology (1951), 2007-02, Vol.156 (2), p.271-276

2007

Volltextzugriff (PDF)

A 24‐week multicentre, randomized, open‐label, parallel‐group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate‐to‐severe plaque psoriasis naive to systemic treatment

British journal of dermatology (1951), 2020-04, Vol.182 (4), p.869-879

2020

Volltextzugriff (PDF)

Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study

Journal of the European Academy of Dermatology and Venereology, 2015-02, Vol.29 (2), p.353-360

2015

Volltextzugriff (PDF)

Efficacy of spesolimab for the treatment of generalized pustular psoriasis flares across pre‐specified patient subgroups in the Effisayil 1 study

Experimental dermatology, 2023-08, Vol.32 (8), p.1279-1283

2023

Volltextzugriff (PDF)

Improvement in aspects of sleep with etanercept and optional adjunctive topical therapy in patients with moderate-to-severe psoriasis: results from the PRISTINE trial

Journal of the European Academy of Dermatology and Venereology, 2014-07, Vol.28 (7), p.900-906

2014

Volltextzugriff (PDF)

Secukinumab is effective in treatment of moderate‐to‐severe plaque psoriasis: real‐life effectiveness and safety from the PROSPECT study

Journal of the European Academy of Dermatology and Venereology, 2020-02, Vol.34 (2), p.310-318

2020

Volltextzugriff (PDF)

Optical coherence tomography-based imaging biomarkers for disease activity monitoring in plaque psoriasis

Journal of the European Academy of Dermatology and Venereology, 2024-05

2024

Volltextzugriff (PDF)

Patients with bullous pemphigoid and comorbid psoriasis present with less blisters and lower serum levels of anti‐BP180 autoantibodies

Journal of the European Academy of Dermatology and Venereology, 2021-04, Vol.35 (4), p.981-987

2021

Volltextzugriff (PDF)

1 – 25 von 311

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(282)
Mit Volltextzugriff
(263)

Publikationsform

Artikel
(307)
Berichte
(3)
Bücher
(1)

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials

Secukinumab is superior to fumaric acid esters in treating patients with moderate‐to‐severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial

Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study

Secukinumab sustains good efficacy and favourable safety in moderate‐to‐severe psoriasis after up to 3 years of treatment: results from a double‐blind extension study

Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest

Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials

Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis: results from a phase IIa open‐label trial and subsequent phase III open‐label extension

Addressing challenges associated with long‐term topical treatment and benefits of proactive management in patients with psoriasis

Gender and age significantly determine patient needs and treatment goals in psoriasis – a lesson for practice

Five‐year efficacy and safety of tildrakizumab in patients with moderate‐to‐severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)

Combined culture and metagenomic analyses reveal significant shifts in the composition of the cutaneous microbiome in psoriasis

Direct comparison of risankizumab and fumaric acid esters in systemic therapy–naïve patients with moderate‐to‐severe plaque psoriasis: a randomized controlled trial

Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial

Alopecia areata development in atopic dermatitis patients treated with dupilumab

Psoriasis patients show signs of insulin resistance

Topology of psoriasis in routine care: results from high‐resolution analysis of 2009 patients

Psoriasis: a possible risk factor for development of coronary artery calcification

A 24‐week multicentre, randomized, open‐label, parallel‐group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate‐to‐severe plaque psoriasis naive to systemic treatment

Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study

Efficacy of spesolimab for the treatment of generalized pustular psoriasis flares across pre‐specified patient subgroups in the Effisayil 1 study

Improvement in aspects of sleep with etanercept and optional adjunctive topical therapy in patients with moderate-to-severe psoriasis: results from the PRISTINE trial

Secukinumab is effective in treatment of moderate‐to‐severe plaque psoriasis: real‐life effectiveness and safety from the PROSPECT study

Optical coherence tomography-based imaging biomarkers for disease activity monitoring in plaque psoriasis

Patients with bullous pemphigoid and comorbid psoriasis present with less blisters and lower serum levels of anti‐BP180 autoantibodies

Suchergebnisse filtern